EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Hemostatic powder TC-325 as first-line treatment option for malignant gastrointestinal bleeding: a cost–utility analysis in the United Kingdom

Dawn M Cooper iD, Benjamin Norton, Neil D Hawkes, Srisha Hebbar, Andrea Telese, John Morris, Rehan Haidry, Alan Barkun

Endoscopy · 01.06.2025 · 57 (06) · 583-592

DOI: 10.1055/a-2495-2813 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endoscopy, erschienen am 01.06.2025. Verfasst von Dawn M Cooper und 7 weiteren Autor:innen. Beteiligte Einrichtung: Cook Medical (UK), Altrincham, United Kingdom of Great Britain and Northern Ireland. Hauptthemen laut MEDLINE: Gastrointestinal Hemorrhage, Hemostatics, Hemostasis, Endoscopic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Randomized controlled trials have shown that hemostatic powder (TC-325) results in greater immediate hemostasis and lower 30-day rebleeding rates than standard endoscopic therapy (SET) for management of malignant upper gastrointestinal bleeding (MUGIB). We explored whether TC-325 would be a cost-effective first-line option for patients with MUGIB compared with SET in the United Kingdom. A decision tree was developed for patients with MUGIB, assessing initial therapy with TC-325 or SET over a 30-day period. Patients with failed initial hemostasis or a rebleed within 30 days underwent further endoscopic treatment, escalation to either transcatheter arterial embolization or surgery, or radiotherapy. Overall 30-day mortality was applied. Costs, in GBP, were based on the United Kingdom National Health Services costs for 2023/2024. Results were reported as incremental differences in cost, quality-adjusted life years (QALY), and net monetary benefit. Deterministic and probabilistic sensitivity analyses and scenario analyses were performed. The cost of treating MUGIB patients with TC-325 was £245.88 lower than treatment with SET, with an incremental increase of 0.001 QALYs. TC-325 remained a cost-saving approach in sensitivity and scenario analyses. Probabilistic sensitivity analysis revealed that TC-325 was more effective and cost saving in 80.1% of simulations (range 67.5%–98.63%). Initial treatment of MUGIB with TC-325 compared with SET was more effective (higher primary hemostasis and lower 30-day rebleeding) and cost saving owing to the requirement for fewer interventions, readmissions, and length of stay. Additional studies are needed to address model uncertainties in the follow-up management of these complex patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal HemorrhageHemostaticsHemostasis, EndoscopicHumansCost-Benefit AnalysisUnited KingdomQuality-Adjusted Life YearsDecision TreesMinerals

Substanzen

HemostaticshemosprayMinerals

Autor:innen und Institutionen

  • Cook Medical (UK), Altrincham, United Kingdom of Great Britain and Northern Ireland.
  • Digestive Disease and Surgery Institute, Cleveland Clinic London, London, United Kingdom of Great Britain and Northern Ireland.
  • Department of Gastroenterology, Royal Glamorgan Hospital, Llantrisant, United Kingdom of Great Britain and Northern Ireland.
  • Department of Gastroenterology, Royal Stoke University Hospital, Stoke-on-Trent, United Kingdom of Great Britain and Northern Ireland.
  • Department of Gastroenterology, Glasgow Royal Infirmary, Glasgow, United Kingdom of Great Britain and Northern Ireland.
  • Division of Gastroenterology, Department of Medicine, McGill University, Montreal, Canada.

ORCID-Profile: Dawn M Cooper

Zitieren

APA

Cooper, D. M., Norton, B., Hawkes, N. D., Hebbar, S., Telese, A., Morris, J., Haidry, R., & Barkun, A. (2025). Hemostatic powder TC-325 as first-line treatment option for malignant gastrointestinal bleeding: a cost–utility analysis in the United Kingdom. Endoscopy, 57(06), 583-592. https://doi.org/10.1055/a-2495-2813

Vancouver

Cooper DM, Norton B, Hawkes ND, Hebbar S, Telese A, Morris J, et al. Hemostatic powder TC-325 as first-line treatment option for malignant gastrointestinal bleeding: a cost–utility analysis in the United Kingdom. Endoscopy. 2025;57(06):583-592. doi:10.1055/a-2495-2813

BibTeX
@article{Cooper2025,
  author = {Cooper, Dawn M and Norton, Benjamin and Hawkes, Neil D and Hebbar, Srisha and Telese, Andrea and Morris, John and Haidry, Rehan and Barkun, Alan},
  title = {Hemostatic powder TC-325 as first-line treatment option for malignant gastrointestinal bleeding: a cost–utility analysis in the United Kingdom},
  journal = {Endoscopy},
  year = {2025},
  volume = {57},
  number = {06},
  pages = {583--592},
  doi = {10.1055/a-2495-2813}
}
Kostenlos starten →